STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma
The development of clinical agents remains a costly and time-consuming process. Although identification of new uses of existing drugs has been recognized as a more efficient approach for drug discovery than development of novel drugs, little screening of drugs that might be used for a rare malignant...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
D.A. Spandidos
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5117998/ |